Stockscreener 앱 받기
3.40
2.02%
-0.07
시간 외 거래:
3.45
0.05
+1.47%
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Don't Ignore The Insider Selling In Rocket Pharmaceuticals - simplywall.st
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Executive Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock - MarketBeat
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock - MarketBeat
Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding - Stock Titan
RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares - Stock Titan
Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals - Stock Titan
Rocket Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Rocket Pharmaceuticals Inc (RCKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5 - Moomoo
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026) - Stock Titan
TD Cowen Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus - Yahoo Finance
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside - TradingView
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15 - GuruFocus
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a shareEarnings Preview - TradingView
ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12 - Bitget
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - BioSpace
ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings - Quiver Quantitative
Rocket Pharmaceuticals: Q2 Earnings Snapshot - barchart.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
Rocket Pharmaceuticals Q2 adj EPS $(0.37) misses $0.24 estimate - scanx.trade
BRIEF-Rocket Pharmaceuticals Q2 EPS USD 1.08 - Bitget
Rocket Pharmaceuticals reports Q2 2026 net income $123.2M, cash $283.7M, eyes Danon pivotal progress - TradingView
Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 6c; offers guidance - streetinsider.com
ROCKET PHARMACEUTICALS, INC. Q2 2026: Revenue $0 Net income $123.2M, EPS $1.08— 10-Q Summary - TradingView
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale - TradingView
Rocket Pharmaceuticals (NASDAQ:RCKT) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Rocket Pharmaceuticals Inc (RCKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
How (RCKT) Movements Inform Risk Allocation Models - Stock Traders Daily
Rocket Pharmaceuticals, Inc. Revenue Breakdown – BOATS:RCKTW - TradingView
Form 4 Rocket Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com Nigeria
BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Rocket Pharmaceuticals reports positive safety update for RP-A501 in Phase 2 Danon trial - TradingView
Rocket Pharma reports early safety data for Danon disease therapy By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.com
Rocket Pharma reports early safety data for Danon disease therapy - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Raised to Hold at Wall Street Zen - MarketBeat
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a 192% Potential Upside in Genetic Therapy Innovations - DirectorsTalk Interviews
Rocket Pharmaceuticals (RCKT) to Release Quarterly Earnings on Thursday - MarketBeat
Rocket Pharmaceuticals: Can The AAV9 Cardiovascular Pipeline Justify The Current Valuation? (NASDAQ:RCKT) - Seeking Alpha
Maverick Capital Ltd. Purchases 1,054,262 Shares of Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals Inc (RCKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rocket Pharmaceuticals Inc (RCKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RCKT|Rocket Pharmaceuticals Inc|Price:3.240|Chg%:+0.050 - TradingKey
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
If You Invested $1,000 in Rocket Pharmaceu (RCKT) - Stock Titan
Class Action Lawsuit Filed: Rocket Pharmaceuticals, Inc. (RCKT)Join by August 11, 2025Contact Levi & Korsinsky - The National Law Review
Rocket Pharmaceuticals, Inc. Revenue Breakdown – MUN:9IP1 - TradingView
Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a Potential 186% Upside in Genetic Therapy Innovation - DirectorsTalk Interviews
Frontier tech research, news & data - MLQ.ai
Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends - Ad-hoc-news.de
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks - TradingView
Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1 - TradingView
Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW - TradingView
1.80%
1.77%
자본화:
|
볼륨(24시간):